AssetMark’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
AssetMark's SYRE Position: Q3 2026 in Review
AssetMark opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 7,232 shares worth $644K. The stake represents ﹤0.01% of the portfolio and ranks #1186 among its holdings.
193 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- AssetMark held 7,232 shares of Spyre Therapeutics worth $644K as of Q3 2026.
- Spyre Therapeutics was a new AssetMark position in Q3 2026.
- Spyre Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1186 holding.
- 193 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.